Download A4Medicine Mobile App
Empower Your RCGP AKT Journey: Master the MCQs with Us! 🚀
This table provides a summarised overview of injectable progesterone contraception, focusing on medroxyprogesterone acetate and DMPA.
| Category | Details |
|---|---|
| Labeled Indications | Contraception, Amenorrhea (tablet), Uterine bleeding (tablet), Hyperplasia prevention (tablet), Endometrial carcinoma, Endometriosis |
| Mode of Action | Prevents ovulation, Actions on endometrial/cervical mucus, Inhibits GnRH, Prevents follicular maturation/ovulation/implantation |
| Dosing Interval | Every 13 weeks (both i.m. & s.c. DMPA); Can extend to 14 weeks without added precautions |
| Efficacy | Failure rate: 0.2% in first year; Long-acting reversible; More clinic visits than with implants/IUDs |
| Side Effects | Common: Menstrual pattern changes, Fertility delay, Weight gain Less Common: Heavy bleeding, Anaphylaxis, Galactorrhoea |
| Client Suitability Assessment | Clinical history, Examine risks of STIs, Medical & family history, Past contraceptive use, Evaluate osteoporosis risks |
| Additional Info on DMPA | Highly effective, Private use, Quarterly dosing, BMD loss with possible recovery, No confirmed fracture data in adolescents/adults, Suitable for up to 2 years considering BMD effects |
References
1 Sathe A, Gerriets V. Medroxyprogesterone. [Updated 2022 Jun 30]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK559192/
2 https://www.wossexualhealthmcn.scot.nhs.uk/wp-content/uploads/2022/03/WEDB631.pdf
Try our Free Plan to get the full article.
